Navigation Links
Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
Date:11/8/2010

SAN DIEGO, Nov. 8, 2010 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) announced today that Christopher J. Reinhard, Cardium's Chairman and Chief Executive Officer will present at the LifeTech Capital Miami Medical Investors Conference on November 12, 2010 at 2:00 p.m. Eastern.  The conference will take place at the JW Marriott Marquis in Miami.  Although this presentation will not be webcast, investors can access the Company's presentation slides now available at Cardium's website at http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-presentations.  

(Logo:  http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations.  Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.  News from Cardium is located at www.cardiumthx.com.

Copyright 2010 Cardium Therapeutics, Inc.  All rights reserved. For Terms of Use Privacy Policy, please visit www.cardiumthx.com. Cardium Therapeutics™ Generx® and MedPodium™ are trademarks of Cardium Therapeutics, Inc.Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, Appexium™ and Linee™ are trademarks of Tissue Repair Company. (Other trademarks belong to their respective owners)


'/>"/>
SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
2. Cardium to Present at 10th Annual Biotech in Europe Investor Forum
3. Cardium Regains Listing Compliance With NYSE Amex
4. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
5. Cardiums Exchange Listing Compliance Plan Accepted by NYSE AMEX
6. Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
7. Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
8. Cardium Completes $6.0 Million Registered Direct Offering
9. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
10. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
11. Cardium Regains Listing Compliance with NYSE Amex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... today announced the three Winners and six Finalists of the 2017 Blavatnik Regional ... by the Blavatnik Family Foundation and administered by the New York Academy of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
Breaking Biology Technology:
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... to grow at a CAGR of 30.37% during the period 2017-2021. ... been prepared based on an in-depth market analysis with inputs from ... prospects over the coming years. The report also includes a discussion ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
Breaking Biology News(10 mins):